Ruhua Luo, Zhongyu Yue, Qian Yang, Honghua Zhang, Tian Xie, Shuling Wang, Qingchang Tian. In situ repolarization of Tumor-Associated Macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.01.009
Citation:
Ruhua Luo, Zhongyu Yue, Qian Yang, Honghua Zhang, Tian Xie, Shuling Wang, Qingchang Tian. In situ repolarization of Tumor-Associated Macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.01.009
Ruhua Luo, Zhongyu Yue, Qian Yang, Honghua Zhang, Tian Xie, Shuling Wang, Qingchang Tian. In situ repolarization of Tumor-Associated Macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.01.009
Citation:
Ruhua Luo, Zhongyu Yue, Qian Yang, Honghua Zhang, Tian Xie, Shuling Wang, Qingchang Tian. In situ repolarization of Tumor-Associated Macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.01.009
In situ repolarization of Tumor-Associated Macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy
a. College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China;
b. Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China;
c. Department of Pharmacy, Hankou Hospital, Wuhan, Hubei 430012, China
Funds:
This work was supported by Zhejiang Provincial Natural Science Foundation of China (LY20H160008), the Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China under Grant No. LHDMZ22H300001, National Natural Science Foundation of China (China, 82074052).
The conversion of tumor-associated macrophages (TAMs) from M2 phenotype to M1 phenotype could reverse the immunosuppression associated with the tumor microenvironment. Here, we constructed M2 phenotype macrophage-targeted Lipo@CpG-FA by encapsulating CpG ODNs. The combination of Lipo@CpG-FA with FA-Lipo@Ele-AS1411 caused regression and inhibition of 4T1 breast cancers by reversing the M2-TAMs mediated immunosuppression and efficiently inducing effector T cell activation in the tumor microenvironment. In addition to antitumor effects, Elemene (Ele) could inhibit the effect M2 macrophage proliferation by enhancing the therapeutic effects. The application of this strategy may be potentially expanded for cancer therapy in combination with other therapeutics.
J.A. Joyce, D.T. Fearon, T cell exclusion, immune privilege, and the tumor microenvironment, Science 348 (2015) 74-80.
[2]
R. Noy, J.W. Pollard, Tumor-associated macrophages: From mechanisms to therapy, Immunity 41 (2014) 49-61.
[3]
R. Sumitomo, T. Hirai, M. Fujita, et al., PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer, Lung Cancer 136 (2019) 136-144.
[4]
B. Zhai, N. Zhang, X. Han, et al., Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review, Biomed. Pharmacother. 114 (2019), 108812.
00029-700f414a4-45bb-4fae-9e18-33f374ba26d7.jpg)
DownLoad: